Clinical Trial Update: Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

View source ↗

Summary

The page notes that the expanded access program for taletrectinib in patients with ROS1-positive non-small cell lung cancer is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taletrectinib (taletrectinib)

Snippet

Sponsor: Nuvation Bio Inc. | Conditions: Lung Neoplasms, Respiratory Tract Neoplasms | Status: NO_LONGER_AVAILABLE